Evidence map›Paper›PMID 28148472›Full record

ArticleJMIR public health and surveillance2017

Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis.

Laurie S Anderson, Heidi G Bell, Michael Gilbert, Julie E Davidson, Christina Winter, Monica J Barratt, Beta Win, Jeffery L Painter, Christopher Menone, Jonathan Sayegh and 1 more

Open access · goldAbstract read
In one paragraph

Article in JMIR public health and surveillance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
21.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 6 countries.

Laurie S Anderson *GlaxoSmithKlineResearch Triangle Park, NCUnited States.ORCID 0000-0001-9489-3855
Heidi G Bell *Gyra MediPharm ConsultingResearch Triangle Park, NCUnited States.ORCID 0000-0003-2468-055X
Michael GilbertEpidemico, IncBoston, MAUnited States.ORCID 0000-0003-4200-6104
Julie E DavidsonGlaxoSmithKlineStockley Park, MiddlesexUnited Kingdom.ORCID 0000-0003-2185-151X
Christina WinterGlaxoSmithKlineStockley Park, MiddlesexUnited Kingdom.ORCID 0000-0002-3423-3422
Monica J BarrattNational Drug and Alcohol Research Centre, UNSW AustraliaRandwickAustralia.ORCID 0000-0002-1015-9379
Beta WinGlaxoSmithKlineStockley Park, MiddlesexUnited Kingdom.ORCID 0000-0001-5790-4930
Jeffery L PainterGlaxoSmithKlineResearch Triangle Park, NCUnited States.ORCID 0000-0001-9651-9904
Christopher MenoneEpidemico, IncBoston, MAUnited States.ORCID 0000-0003-0197-9997
Jonathan SayeghKadiant AnalyticsBoston, MAUnited States.ORCID 0000-0003-3847-1775
Nabarun DasguptaEpidemico, IncBoston, MAUnited States.ORCID 0000-0002-4098-605X
Centro Universitario Columbia · MXGlaxoSmithKline (United Kingdom) · GBResearch Triangle Park Foundation · USnLIGHT (United States) · USSystems Analytics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe nonmedical use of pharmaceutical products has become a significant public health concern. Traditionally, the evaluation of nonmedical use has focused on controlled substances with addiction risk. Currently, there is no effective means of evaluating the nonmedical use of noncontrolled antidepressants.

objectiveSocial listening, in the context of public health sometimes called infodemiology or infoveillance, is the process of identifying and assessing what is being said about a company, product, brand, or individual, within forms of electronic interactive media. The objectives of this study were (1) to determine whether content analysis of social listening data could be utilized to identify posts discussing potential misuse or nonmedical use of bupropion and two comparators, amitriptyline and venlafaxine, and (2) to describe and characterize these posts.

methodsSocial listening was performed on all publicly available posts cumulative through July 29, 2015, from two harm-reduction Web forums, Bluelight and Opiophile, which mentioned the study drugs. The acquired data were stripped of personally identifiable identification (PII). A set of generic, brand, and vernacular product names was used to identify product references in posts. Posts were obtained using natural language processing tools to identify vernacular references to drug misuse-related Preferred Terms from the English Medical Dictionary for Regulatory Activities (MedDRA) version 18 terminology. Posts were reviewed manually by coders, who extracted relevant details.

resultsA total of 7756 references to at least one of the study antidepressants were identified within posts gathered for this study. Of these posts, 668 (8.61%, 668/7756) referenced misuse or nonmedical use of the drug, with bupropion accounting for 438 (65.6%, 438/668). Of the 668 posts, nonmedical use was discouraged by 40.6% (178/438), 22% (22/100), and 18.5% (24/130) and encouraged by 12.3% (54/438), 10% (10/100), and 10.8% (14/130) for bupropion, amitriptyline, and venlafaxine, respectively. The most commonly reported desired effects were similar to stimulants with bupropion, sedatives with amitriptyline, and dissociatives with venlafaxine. The nasal route of administration was most frequently reported for bupropion, whereas the oral route was most frequently reported for amitriptyline and venlafaxine. Bupropion and venlafaxine were most commonly procured from health care providers, whereas amitriptyline was most commonly obtained or stolen from a third party. The Fleiss kappa for interrater agreement among 20 items with 7 categorical response options evaluated by all 11 raters was 0.448 (95% CI 0.421-0.457).

conclusionsSocial listening, conducted in collaboration with harm-reduction Web forums, offers a valuable new data source that can be used for monitoring nonmedical use of antidepressants. Additional work on the capabilities of social listening will help further delineate the benefits and limitations of this rapidly evolving data source.

Indexed as

amitriptylinebupropioncommunity-based participatory researchharm reductionInternetpharmacovigilanceprescription drug misusesocial mediasubstance-related disordersvenlafaxine hydrochloride

Identifiers

PMID28148472
PMCPMC5311422
OpenAlexW2583291693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.